12/3
03:31 pm
oncy
UPDATE -- The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality
Low
Report
UPDATE -- The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality
12/3
11:43 am
oncy
Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]
Low
Report
Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]
11/25
01:54 pm
oncy
Oncolytics Biotech (NASDAQ:ONCY) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Oncolytics Biotech (NASDAQ:ONCY) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/20
04:05 pm
oncy
Oncolytics Biotech® Provides Update on Special Meeting of Shareholders
Low
Report
Oncolytics Biotech® Provides Update on Special Meeting of Shareholders
11/19
07:04 pm
oncy
All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy [Yahoo! Finance]
Medium
Report
All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy [Yahoo! Finance]
11/19
09:55 am
oncy
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer [Yahoo! Finance]
Neutral
Report
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer [Yahoo! Finance]
11/19
09:45 am
oncy
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
Low
Report
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
11/19
09:00 am
oncy
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer
High
Report
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer
11/17
08:06 am
oncy
Oncolytics Biotech (NASDAQ:ONCY) had its price target raised by analysts at HC Wainwright from $5.00 to $10.00. They now have a "buy" rating on the stock.
Low
Report
Oncolytics Biotech (NASDAQ:ONCY) had its price target raised by analysts at HC Wainwright from $5.00 to $10.00. They now have a "buy" rating on the stock.
11/4
08:00 am
oncy
Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy
High
Report
Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy
10/28
07:30 am
oncy
Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care
Low
Report
Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care
10/21
07:28 am
oncy
Oncolytics Biotech (NASDAQ:ONCY) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Neutral
Report
Oncolytics Biotech (NASDAQ:ONCY) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
10/20
09:00 am
oncy
Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada
Low
Report
Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada
9/29
08:37 am
oncy
Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study [Yahoo! Finance]
Low
Report
Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study [Yahoo! Finance]
9/29
08:30 am
oncy
Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study
Low
Report
Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study
9/16
07:00 am
oncy
Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion
Medium
Report
Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion
9/8
09:59 am
oncy
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market [Globe and Mail, The (Toronto, Canada)]
Low
Report
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market [Globe and Mail, The (Toronto, Canada)]
9/8
09:48 am
oncy
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market [Globe and Mail, The (Toronto, Canada)]
Low
Report
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market [Globe and Mail, The (Toronto, Canada)]
9/8
07:00 am
oncy
Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions
High
Report
Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions